Compound ID | 1281
Class: Cell-wall synthesis inhibitor (PBP3 inhibitor)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Activity against P. aeruginosa In Vitro |
| Institute where first reported: | Entasis Therapeutics |
| Year first mentioned: | 2019 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | High porin permeation |